61,682 Shares in Evolus, Inc. (NASDAQ:EOLS) Acquired by XTX Topco Ltd

XTX Topco Ltd acquired a new stake in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 61,682 shares of the company's stock, valued at approximately $742,000. XTX Topco Ltd owned about 0.10% of Evolus as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the company. Barclays PLC boosted its stake in shares of Evolus by 12.9% during the fourth quarter. Barclays PLC now owns 105,786 shares of the company's stock valued at $1,167,000 after purchasing an additional 12,124 shares during the period. Frontier Capital Management Co. LLC purchased a new stake in shares of Evolus during the fourth quarter valued at $2,648,000. Raymond James Financial Inc. purchased a new stake in shares of Evolus during the fourth quarter valued at $575,000. Comerica Bank purchased a new stake in shares of Evolus during the fourth quarter valued at $312,000. Finally, Tang Capital Management LLC boosted its stake in shares of Evolus by 3.1% during the fourth quarter. Tang Capital Management LLC now owns 4,997,399 shares of the company's stock valued at $55,171,000 after purchasing an additional 150,000 shares during the period. Institutional investors own 90.69% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. HC Wainwright lowered their price objective on shares of Evolus from $27.00 to $20.00 and set a "buy" rating for the company in a research note on Wednesday. Needham & Company LLC reaffirmed a "hold" rating and issued a $22.00 price objective on shares of Evolus in a research note on Wednesday. Finally, BTIG Research lowered their price objective on shares of Evolus from $21.00 to $18.00 and set a "buy" rating for the company in a research note on Wednesday. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Evolus presently has a consensus rating of "Moderate Buy" and a consensus price target of $21.25.

Evolus Stock Down 2.9%

Shares of EOLS stock traded down $0.18 during mid-day trading on Friday, hitting $5.90. 1,286,122 shares of the stock traded hands, compared to its average volume of 1,080,074. The stock has a market cap of $381.29 million, a P/E ratio of -6.04 and a beta of 1.12. The stock's fifty day moving average is $9.32 and its two-hundred day moving average is $11.19. Evolus, Inc. has a 52-week low of $5.85 and a 52-week high of $17.82. The company has a debt-to-equity ratio of 22.00, a current ratio of 2.27 and a quick ratio of 2.16.

Insider Activity at Evolus

In related news, insider Rui Avelar sold 3,385 shares of the stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $9.87, for a total value of $33,409.95. Following the completion of the transaction, the insider directly owned 359,082 shares of the company's stock, valued at $3,544,139.34. This trade represents a 0.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Albert G. White III acquired 20,000 shares of the firm's stock in a transaction that occurred on Monday, June 9th. The stock was bought at an average cost of $9.45 per share, with a total value of $189,000.00. Following the completion of the transaction, the director directly owned 50,378 shares in the company, valued at $476,072.10. The trade was a 65.84% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 153,571 shares of company stock valued at $1,537,090. Company insiders own 5.90% of the company's stock.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.